Product News

Share this article:

GlaxoSmithKline agreed to sell US commercial rights for Wellbutrin XL, an antidepressant, to Biovail Corp. for $510 million, according to a Bloomberg report. Wellbutrin's patent expired over two years ago. GSK will retain rights to the drug outside the US.

 

Rockville, MD-based biotech Vanda Pharmaceuticals secured an FDA approval for its first product, a schizophrenia treatment called Fanapt (iloperidone). The drug will be available in pharmacies later this year, according to a company statement.  

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters